The frequency of responding IFN-γ-producing CD4+ T cells specific to individual epitopes was quantified, in each of the six groups of COVID-19 patients, using ELISpot assay (i.e., number of IFN-γ-spot forming CD4+ T cells or “SFCs”) (Figure 1). This evidence concerns the gene IFNG and COVID-19.